Global Gastrointestinal Disorder Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food. Gastrointestinal disorders includes irritable bowel syndrome, gastroesophageal reflux diseases and peptic ulcer diseases.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Gastrointestinal Disorder Therapeutics estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.

Increasing incidences of gastrointestinal disorders that demands treatment by these therapeutics will boost the growth of this market.

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Gastrointestinal Disorder Therapeutics companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Gastrointestinal Disorder Therapeutics market. Further, it explains the major drivers and regional dynamics of the global Gastrointestinal Disorder Therapeutics market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

AstraZeneca

Takeda Pharmaceutical

Johnson & Johnson

Eisai

Abbott Laboratories

Salix Pharmaceuticals

Bausch Health

Allergan

Bayer

UCB

AbbVie

GlaxoSmithKline

Astellas Pharma

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Irritable Bowel Syndrome (IBS)

Chronic Constipation (CC)

Ulcerative Colitis (UC)

Hospitals

Clinics

Others

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Gastrointestinal Disorder Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Gastrointestinal Disorder Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Gastrointestinal Disorder Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Gastrointestinal Disorder Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastrointestinal Disorder Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Gastrointestinal Disorder Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Gastrointestinal Disorder Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including AstraZeneca, Takeda Pharmaceutical, Johnson & Johnson, Eisai, Abbott Laboratories, Salix Pharmaceuticals, Bausch Health, Allergan and Bayer, etc.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gastrointestinal Disorder Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Irritable Bowel Syndrome (IBS)

1.2.3 Chronic Constipation (CC)

1.2.4 Ulcerative Colitis (UC)

1.3 Market by Application

1.3.1 Global Gastrointestinal Disorder Therapeutics Market Growth Rate by Application: 2017 VS 2021 VS 2028

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

2.1 Global Gastrointestinal Disorder Therapeutics Market Size (2017-2028)

2.2 Gastrointestinal Disorder Therapeutics Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028

2.3 Global Gastrointestinal Disorder Therapeutics Market Size by Region (2017-2022)

2.4 Global Gastrointestinal Disorder Therapeutics Market Size Forecast by Region (2023-2028)

2.5 Global Top Gastrointestinal Disorder Therapeutics Countries Ranking by Market Size

3.1 Global Gastrointestinal Disorder Therapeutics Revenue by Players

3.1.1 Global Gastrointestinal Disorder Therapeutics Revenue by Players (2017-2022)

3.1.2 Global Gastrointestinal Disorder Therapeutics Market Share by Players (2017-2022)

3.2 Global Gastrointestinal Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Company Covered: Ranking by Gastrointestinal Disorder Therapeutics Revenue

3.4 Global Gastrointestinal Disorder Therapeutics Market Concentration Ratio

3.4.1 Global Gastrointestinal Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Disorder Therapeutics Revenue in 2021

3.5 Global Gastrointestinal Disorder Therapeutics Key Players Head office and Area Served

3.6 Key Players Gastrointestinal Disorder Therapeutics Product Solution and Service

3.7 Date of Enter into Gastrointestinal Disorder Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Gastrointestinal Disorder Therapeutics Historic Revenue by Type (2017-2022)

4.2 Global Gastrointestinal Disorder Therapeutics Forecasted Revenue by Type (2023-2028)

5.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Application (2017-2022)

5.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Application (2023-2028)

6.1 North America Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022)

6.2 North America Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2028)

6.3 North America Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2028)

6.4 North America Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2028)

6.4.1 U.S.

6.4.2 Canada

7.1 Europe Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022)

7.2 Europe Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2028)

7.3 Europe Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2028)

7.4 Europe Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2028)

7.4.1 Germany

7.4.2 France

7.4.3 U.K.

7.4.4 Italy

7.4.5 Russia

8.1 Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022)

8.2 Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2028)

8.3 Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2028)

8.4 Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Region (2017-2028)

8.4.1 China

8.4.2 Japan

8.4.3 South Korea

8.4.4 India

8.4.5 Australia

8.4.6 Taiwan

8.4.7 Indonesia

8.4.8 Thailand

8.4.9 Malaysia

8.4.10 Philippines

8.4.11 Vietnam

9.1 Latin America Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022)

9.2 Latin America Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2028)

9.3 Latin America Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2028)

9.4 Latin America Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2028)

9.4.1 Mexico

9.4.2 Brazil

9.4.3 Argentina

10.1 Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022)

10.2 Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2028)

10.3 Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2028)

10.4 Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2028)

10.4.1 Turkey

10.4.2 Saudi Arabia

10.4.3 UAE

11.1 AstraZeneca

11.1.1 AstraZeneca Company Details

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Gastrointestinal Disorder Therapeutics Products and Services

11.1.4 AstraZeneca Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.1.5 AstraZeneca Gastrointestinal Disorder Therapeutics SWOT Analysis

11.1.6 AstraZeneca Recent Developments

11.2 Takeda Pharmaceutical

11.2.1 Takeda Pharmaceutical Company Details

11.2.2 Takeda Pharmaceutical Business Overview

11.2.3 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Products and Services

11.2.4 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.2.5 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics SWOT Analysis

11.2.6 Takeda Pharmaceutical Recent Developments

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Details

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Gastrointestinal Disorder Therapeutics Products and Services

11.3.4 Johnson & Johnson Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.3.5 Johnson & Johnson Gastrointestinal Disorder Therapeutics SWOT Analysis

11.3.6 Johnson & Johnson Recent Developments

11.4 Eisai

11.4.1 Eisai Company Details

11.4.2 Eisai Business Overview

11.4.3 Eisai Gastrointestinal Disorder Therapeutics Products and Services

11.4.4 Eisai Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.4.5 Eisai Gastrointestinal Disorder Therapeutics SWOT Analysis

11.4.6 Eisai Recent Developments

11.5 Abbott Laboratories

11.5.1 Abbott Laboratories Company Details

11.5.2 Abbott Laboratories Business Overview

11.5.3 Abbott Laboratories Gastrointestinal Disorder Therapeutics Products and Services

11.5.4 Abbott Laboratories Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.5.5 Abbott Laboratories Gastrointestinal Disorder Therapeutics SWOT Analysis

11.5.6 Abbott Laboratories Recent Developments

11.6 Salix Pharmaceuticals

11.6.1 Salix Pharmaceuticals Company Details

11.6.2 Salix Pharmaceuticals Business Overview

11.6.3 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Products and Services

11.6.4 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.6.5 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics SWOT Analysis

11.6.6 Salix Pharmaceuticals Recent Developments

11.7 Bausch Health

11.7.1 Bausch Health Company Details

11.7.2 Bausch Health Business Overview

11.7.3 Bausch Health Gastrointestinal Disorder Therapeutics Products and Services

11.7.4 Bausch Health Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.7.5 Bausch Health Gastrointestinal Disorder Therapeutics SWOT Analysis

11.7.6 Bausch Health Recent Developments

11.8 Allergan

11.8.1 Allergan Company Details

11.8.2 Allergan Business Overview

11.8.3 Allergan Gastrointestinal Disorder Therapeutics Products and Services

11.8.4 Allergan Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.8.5 Allergan Gastrointestinal Disorder Therapeutics SWOT Analysis

11.8.6 Allergan Recent Developments

11.9 Bayer

11.9.1 Bayer Company Details

11.9.2 Bayer Business Overview

11.9.3 Bayer Gastrointestinal Disorder Therapeutics Products and Services

11.9.4 Bayer Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.9.5 Bayer Gastrointestinal Disorder Therapeutics SWOT Analysis

11.9.6 Bayer Recent Developments

11.10 UCB

11.10.1 UCB Company Details

11.10.2 UCB Business Overview

11.10.3 UCB Gastrointestinal Disorder Therapeutics Products and Services

11.10.4 UCB Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.10.5 UCB Gastrointestinal Disorder Therapeutics SWOT Analysis

11.10.6 UCB Recent Developments

11.11 AbbVie

11.11.1 AbbVie Company Details

11.11.2 AbbVie Business Overview

11.11.3 AbbVie Gastrointestinal Disorder Therapeutics Products and Services

11.11.4 AbbVie Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.11.5 AbbVie Recent Developments

11.12 GlaxoSmithKline

11.12.1 GlaxoSmithKline Company Details

11.12.2 GlaxoSmithKline Business Overview

11.12.3 GlaxoSmithKline Gastrointestinal Disorder Therapeutics Products and Services

11.12.4 GlaxoSmithKline Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.12.5 GlaxoSmithKline Recent Developments

11.13 Astellas Pharma

11.13.1 Astellas Pharma Company Details

11.13.2 Astellas Pharma Business Overview

11.13.3 Astellas Pharma Gastrointestinal Disorder Therapeutics Products and Services

11.13.4 Astellas Pharma Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022)

11.13.5 Astellas Pharma Recent Developments

12.1 Gastrointestinal Disorder Therapeutics Market Trends

12.2 Gastrointestinal Disorder Therapeutics Market Drivers

12.3 Gastrointestinal Disorder Therapeutics Market Challenges

12.4 Gastrointestinal Disorder Therapeutics Market Restraints

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Author Details

List of Tables

    Table 1. Global Gastrointestinal Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

    Table 2. Key Players of Irritable Bowel Syndrome (IBS)

    Table 3. Key Players of Chronic Constipation (CC)

    Table 4. Key Players of Ulcerative Colitis (UC)

    Table 5. Global Gastrointestinal Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

    Table 6. Global Gastrointestinal Disorder Therapeutics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028

    Table 7. Global Gastrointestinal Disorder Therapeutics Revenue by Region (2017-2022) & (US$ Million)

    Table 8. Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Region (2017-2022)

    Table 9. Global Gastrointestinal Disorder Therapeutics Revenue by Players (2017-2022) & (US$ Million)

    Table 10. Global Gastrointestinal Disorder Therapeutics Market Share by Players (2017-2022)

    Table 11. Global Top Gastrointestinal Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Disorder Therapeutics as of 2021)

    Table 12. Ranking of Global Top Gastrointestinal Disorder Therapeutics Companies by Revenue (US$ Million) in 2021

    Table 13. Global 5 Largest Players Market Share by Gastrointestinal Disorder Therapeutics Revenue (CR5 and HHI) & (2017-2022)

    Table 14. Key Players Headquarters and Area Served

    Table 15. Key Players Gastrointestinal Disorder Therapeutics Product Solution and Service

    Table 16. Date of Key Manufacturers Enter into Gastrointestinal Disorder Therapeutics Market

    Table 17. Mergers & Acquisitions, Expansion Plans

    Table 18. Global Gastrointestinal Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)

    Table 19. Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2017-2022)

    Table 20. Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 21. Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2023-2028)

    Table 22. Global Gastrointestinal Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)

    Table 23. Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2017-2022)

    Table 24. Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 25. Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2023-2028)

    Table 26. North America Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022) & (US$ Million)

    Table 27. North America Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2022) & (US$ Million)

    Table 28. North America Gastrointestinal Disorder Therapeutics Revenue by Type (2023-2028) & (US$ Million)

    Table 29. North America Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2022) & (US$ Million)

    Table 30. North America Gastrointestinal Disorder Therapeutics Revenue by Application (2023-2028) & (US$ Million)

    Table 31. North America Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2022) & (US$ Million)

    Table 32. North America Gastrointestinal Disorder Therapeutics Revenue by Country (2023-2028) & (US$ Million)

    Table 33. Europe Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022) & (US$ Million)

    Table 34. Europe Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2022) & (US$ Million)

    Table 35. Europe Gastrointestinal Disorder Therapeutics Revenue by Type (2023-2028) & (US$ Million)

    Table 36. Europe Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2022) & (US$ Million)

    Table 37. Europe Gastrointestinal Disorder Therapeutics Revenue by Application (2023-2028) & (US$ Million)

    Table 38. Europe Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2022) & (US$ Million)

    Table 39. Europe Gastrointestinal Disorder Therapeutics Revenue by Country (2023-2028) & (US$ Million)

    Table 40. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022) & (US$ Million)

    Table 41. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2022) & (US$ Million)

    Table 42. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Type (2023-2028) & (US$ Million)

    Table 43. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2022) & (US$ Million)

    Table 44. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Application (2023-2028) & (US$ Million)

    Table 45. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Region (2017-2022) & (US$ Million)

    Table 46. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue by Region (2023-2028) & (US$ Million)

    Table 47. Latin America Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022) & (US$ Million)

    Table 48. Latin America Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2022) & (US$ Million)

    Table 49. Latin America Gastrointestinal Disorder Therapeutics Revenue by Type (2023-2028) & (US$ Million)

    Table 50. Latin America Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2022) & (US$ Million)

    Table 51. Latin America Gastrointestinal Disorder Therapeutics Revenue by Application (2023-2028) & (US$ Million)

    Table 52. Latin America Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2022) & (US$ Million)

    Table 53. Latin America Gastrointestinal Disorder Therapeutics Revenue by Country (2023-2028) & (US$ Million)

    Table 54. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Company (2020-2022) & (US$ Million)

    Table 55. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Type (2017-2022) & (US$ Million)

    Table 56. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Type (2023-2028) & (US$ Million)

    Table 57. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Application (2017-2022) & (US$ Million)

    Table 58. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Application (2023-2028) & (US$ Million)

    Table 59. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Country (2017-2022) & (US$ Million)

    Table 60. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue by Country (2023-2028) & (US$ Million)

    Table 61. AstraZeneca Company Details

    Table 62. AstraZeneca Business Overview

    Table 63. AstraZeneca Gastrointestinal Disorder Therapeutics Product and Services

    Table 64. AstraZeneca Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 65. AstraZeneca Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 66. AstraZeneca Recent Developments

    Table 67. Takeda Pharmaceutical Company Details

    Table 68. Takeda Pharmaceutical Business Overview

    Table 69. Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Product and Services

    Table 70. Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 71. Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 72. Takeda Pharmaceutical Recent Developments

    Table 73. Johnson & Johnson Company Details

    Table 74. Johnson & Johnson Business Overview

    Table 75. Johnson & Johnson Gastrointestinal Disorder Therapeutics Product and Services

    Table 76. Johnson & Johnson Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 77. Johnson & Johnson Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 78. Johnson & Johnson Recent Developments

    Table 79. Eisai Company Details

    Table 80. Eisai Business Overview

    Table 81. Eisai Gastrointestinal Disorder Therapeutics Product and Services

    Table 82. Eisai Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 83. Eisai Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 84. Eisai Recent Developments

    Table 85. Abbott Laboratories Company Details

    Table 86. Abbott Laboratories Business Overview

    Table 87. Abbott Laboratories Gastrointestinal Disorder Therapeutics Product and Services

    Table 88. Abbott Laboratories Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 89. Abbott Laboratories Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 90. Abbott Laboratories Recent Developments

    Table 91. Salix Pharmaceuticals Company Details

    Table 92. Salix Pharmaceuticals Business Overview

    Table 93. Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Product and Services

    Table 94. Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 95. Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 96. Salix Pharmaceuticals Recent Developments

    Table 97. Bausch Health Company Details

    Table 98. Bausch Health Business Overview

    Table 99. Bausch Health Gastrointestinal Disorder Therapeutics Product and Services

    Table 100. Bausch Health Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 101. Bausch Health Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 102. Bausch Health Recent Developments

    Table 103. Allergan Company Details

    Table 104. Allergan Business Overview

    Table 105. Allergan Gastrointestinal Disorder Therapeutics Product and Services

    Table 106. Allergan Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 107. Allergan Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 108. Allergan Recent Developments

    Table 109. Bayer Company Details

    Table 110. Bayer Business Overview

    Table 111. Bayer Gastrointestinal Disorder Therapeutics Product and Services

    Table 112. Bayer Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 113. Bayer Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 114. Bayer Recent Developments

    Table 115. UCB Company Details

    Table 116. UCB Business Overview

    Table 117. UCB Gastrointestinal Disorder Therapeutics Product and Services

    Table 118. UCB Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 119. UCB Gastrointestinal Disorder Therapeutics SWOT Analysis

    Table 120. UCB Recent Developments

    Table 121. AbbVie Company Details

    Table 122. AbbVie Business Overview

    Table 123. AbbVie Gastrointestinal Disorder Therapeutics Product and Services

    Table 124. AbbVie Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 125. AbbVie Recent Developments

    Table 126. GlaxoSmithKline Company Details

    Table 127. GlaxoSmithKline Business Overview

    Table 128. GlaxoSmithKline Gastrointestinal Disorder Therapeutics Product and Services

    Table 129. GlaxoSmithKline Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 130. GlaxoSmithKline Recent Developments

    Table 131. Astellas Pharma Company Details

    Table 132. Astellas Pharma Business Overview

    Table 133. Astellas Pharma Gastrointestinal Disorder Therapeutics Product and Services

    Table 134. Astellas Pharma Gastrointestinal Disorder Therapeutics Revenue in Gastrointestinal Disorder Therapeutics Business (2017-2022) & (US$ Million)

    Table 135. Astellas Pharma Recent Developments

    Table 136. Gastrointestinal Disorder Therapeutics Market Trends

    Table 137. Gastrointestinal Disorder Therapeutics Market Drivers

    Table 138. Gastrointestinal Disorder Therapeutics Market Challenges

    Table 139. Gastrointestinal Disorder Therapeutics Market Restraints

    Table 140. Research Programs/Design for This Report

    Table 141. Key Data Information from Secondary Sources

    Table 142. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Gastrointestinal Disorder Therapeutics Sales Market Share by Type: 2021 VS 2028

    Figure 2. Irritable Bowel Syndrome (IBS) Features

    Figure 3. Chronic Constipation (CC) Features

    Figure 4. Ulcerative Colitis (UC) Features

    Figure 5. Global Gastrointestinal Disorder Therapeutics Sales Market Share by Application: 2021 VS 2028

    Figure 6. Hospitals Case Studies

    Figure 7. Clinics Case Studies

    Figure 8. Others Case Studies

    Figure 9. Gastrointestinal Disorder Therapeutics Report Years Considered

    Figure 10. Global Gastrointestinal Disorder Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028

    Figure 11. Global Gastrointestinal Disorder Therapeutics Market Size 2017-2028 (US$ Million)

    Figure 12. Global Gastrointestinal Disorder Therapeutics Market Size Market Share by Region: 2021 VS 2028

    Figure 13. Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Region in 2017 VS 2022

    Figure 14. Global Top 10 Gastrointestinal Disorder Therapeutics Countries Ranking by Market Size (US$ Million) in 2021

    Figure 15. Global Gastrointestinal Disorder Therapeutics Market Share by Players in 2021

    Figure 16. Global Top Gastrointestinal Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Disorder Therapeutics as of 2021)

    Figure 17. The Top 10 and 5 Players Market Share by Gastrointestinal Disorder Therapeutics Revenue in 2021

    Figure 18. North America Gastrointestinal Disorder Therapeutics Revenue Market Share by Company in 2021

    Figure 19. North America Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2017-2028)

    Figure 20. North America Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2017-2028)

    Figure 21. North America Gastrointestinal Disorder Therapeutics Revenue Share by Country (2017-2028)

    Figure 22. U.S. Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 23. Canada Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 24. Europe Gastrointestinal Disorder Therapeutics Revenue Market Share by Company in 2021

    Figure 25. Europe Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2017-2028)

    Figure 26. Europe Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2017-2028)

    Figure 27. Europe Gastrointestinal Disorder Therapeutics Revenue Share by Country (2017-2028)

    Figure 28. Germany Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 29. France Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 30. U.K. Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 31. Italy Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 32. Russia Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 33. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue Market Share by Company in 2021

    Figure 34. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2017-2028)

    Figure 35. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2017-2028)

    Figure 36. Asia Pacific Gastrointestinal Disorder Therapeutics Revenue Share by Region (2017-2028)

    Figure 37. China Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 38. Japan Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 39. South Korea Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 40. India Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 41. Australia Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 42. Taiwan Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 43. Indonesia Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 44. Thailand Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 45. Malaysia Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 46. Philippines Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 47. Vietnam Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 48. Latin America Gastrointestinal Disorder Therapeutics Revenue Market Share by Company in 2021

    Figure 49. Latin America Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2017-2028)

    Figure 50. Latin America Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2017-2028)

    Figure 51. Latin America Gastrointestinal Disorder Therapeutics Revenue Share by Country (2017-2028)

    Figure 52. Mexico Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 53. Brazil Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 54. Argentina Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 55. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue Market Share by Company in 2021

    Figure 56. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue Market Share by Type (2017-2028)

    Figure 57. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue Market Share by Application (2017-2028)

    Figure 58. Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue Share by Country (2017-2028)

    Figure 59. Turkey Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 60. Saudi Arabia Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 61. UAE Gastrointestinal Disorder Therapeutics Revenue (2017-2028) & (US$ Million)

    Figure 62. AstraZeneca Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 63. Takeda Pharmaceutical Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 64. Johnson & Johnson Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 65. Eisai Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 66. Abbott Laboratories Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 67. Salix Pharmaceuticals Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 68. Bausch Health Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 69. Allergan Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 70. Bayer Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 71. UCB Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 72. AbbVie Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 73. GlaxoSmithKline Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 74. Astellas Pharma Revenue Growth Rate in Gastrointestinal Disorder Therapeutics Business (2017-2022)

    Figure 75. Bottom-up and Top-down Approaches for This Report

    Figure 76. Data Triangulation

    Figure 77. Key Executives Interviewed